Kinnate Biopharma Inc.

NasdaqGS:KNTE Stock Report

Market Cap: US$125.1m

Kinnate Biopharma Balance Sheet Health

Financial Health criteria checks 6/6

Kinnate Biopharma has a total shareholder equity of $159.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $173.6M and $14.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$154.03m
EquityUS$159.33m
Total liabilitiesUS$14.28m
Total assetsUS$173.61m

Recent financial health updates

Recent updates

Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

Jun 11
Is Kinnate Biopharma (NASDAQ:KNTE) In A Good Position To Invest In Growth?

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Jan 04
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Sep 21

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Aug 11

We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

May 15
We're Hopeful That Kinnate Biopharma (NASDAQ:KNTE) Will Use Its Cash Wisely

Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

Jan 24
Companies Like Kinnate Biopharma (NASDAQ:KNTE) Are In A Position To Invest In Growth

We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Oct 09
We Think Kinnate Biopharma (NASDAQ:KNTE) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Situation

We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Mar 03
We're Not Very Worried About Kinnate Biopharma's (NASDAQ:KNTE) Cash Burn Rate

Kinnate Biopharma earns bulls as IPO quiet period ends

Dec 28

Financial Position Analysis

Short Term Liabilities: KNTE's short term assets ($158.2M) exceed its short term liabilities ($12.0M).

Long Term Liabilities: KNTE's short term assets ($158.2M) exceed its long term liabilities ($2.3M).


Debt to Equity History and Analysis

Debt Level: KNTE is debt free.

Reducing Debt: KNTE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KNTE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KNTE has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 36.1% each year


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.